Skip to main content
  • About Us
  • News
  • Careers
  • Authorized Partners
  • Products
  • Conditions
  • Education & Events
  • Value-based solutions
  • Support
  • Careers
  • News

COVID-19: Our Current Path Forward

W. L. GORE & ASSOCIATES CELEBRATES THE 50TH ANNIVERSARY OF ePTFE DISCOVERY

Expanded Polytetrafluoroethylene (ePTFE) Serves as a Core Material for Many Gore Innovations

Study Confirms GORE® BIO-A® Tissue Reinforcement a Proven Alternative to Biologics in Hernia Repair

Two-year study demonstrates improved patient satisfaction with Gore material

GORE® EXCLUDER® AAA Endoprosthesis Gore Completes Primary Enrollment for the Gore EXCLUDER® Iliac Branch Clinical Study

62 patients enrolled in US investigational device exemption clinical study to assess first complete, low-profile system for managing common iliac artery aneurysms or aorto-iliac aneurysms

Gore Again Named One of the 100 Best Companies to Work For®

Every year since 1998: That’s how long W. L. Gore & Associates has appeared on the Fortune 100 Best Companies to Work For® list

Nominees Announced for 2016 Pioneers in Performance Awards for North America; Online Voting Opens at www.PioneersInPerformance.com

Awards program honors medical specialists advancing therapy and improving patient and clinical performance through active collaboration

GORE® TIGRIS® Vascular Stent Gains FDA Approval for Treatment of Peripheral Artery Disease

Novel device combines proven technology with modern adaptations to provide support in even the most challenging anatomies

Now Published in the Annals of Surgery: Long-Term Favorable Results Demonstrate GORE® BIO-A® Tissue Reinforcement Efficacy in Complex Ventral Hernia Repairs

Final study results demonstrate for the first time efficacy of long-lasting absorbable biosynthetic mesh in challenging hernia repairs; has potential to end biologics era in hernia repair

First Patient Enrolled in Gore® SCAFFOLD Clinical Study for Carotid Stenting

Pivotal Multicenter Investigational Study Begins at Medical University of South Carolina (MUSC), Evaluating Safety and Efficacy of Innovative GORE® Carotid Stent

Gore Marks Two-Year Primary Endpoint Follow-up Milestone in Study of GORE® CARDIOFORM Septal Occluder for Patent Foramen Ovale (PFO) Closure

Completion of follow -up paves way for REDUCE Clinical Study data submission to FDA for PFO indication

Pagination

  • Load more

Residents of some states have the right to opt-out of the “sharing” or “selling” of their personal information. Gore does not "sell" the personal information of website users. Gore may "share" the personal information of website users, as standard advertising practice meant to offer you a more personalized service.

If you want to opt-out from Gore “sharing” your personal information, click on Opt-Out of Sharing to turn off the targeting cookies that we share with our advertising partners in order to provide you with personalized information. Disabling sharing will stop the use of cookies to targeted advertising but you may still see generic Gore ads.

Please note that your exercising of the rights outlined will have no adverse effect on the price and quality of our goods or services.

Opt-Out of Sharing

You Have Successfully Opted Out of the Sharing of Your Personal Information

Please note that if you clear your cookies and then use another device or browser, etc. your opt-out status is not transferred to the new device or browser.

  • Cookie Settings
  • Support
  • Legal Information
  • Privacy Notice
  • Regulatory Information
  • Trademarks
  • Newsletter
  • Modern Slavery Statement
  • gore.com

Copyright © 2002-2025 | W. L. Gore & Associates, Inc. | Products listed may not be available in all markets.